Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Value of Computed Tomography-Based Computational Fluid Dynamics in the Prediction of Acute Coronary Syndrome.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.

Annals of the rheumatic diseases·2026
Same author

Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.

The Lancet. Rheumatology·2026
Same author

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144.

bioRxiv : the preprint server for biology·2026
Same author

Facial iPPG heatmap patterns based on period-aware autoencoder show association with carotid atherosclerosis towards non-contact hemodynamic assessment.

Computer methods and programs in biomedicine·2026
Same author

Quantification of Binding of Small Molecules to Native Kinases by Flow Cytometry Reveals Divergence from Biochemical Affinities.

Journal of the American Chemical Society·2026

相关实验视频

Updated: Jun 20, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.4K

重组抗体产生稳定的CHOK1池稳定性研究

Bailin Tu1, Zhihong Lin1, Jeff Moore1

  • 1Biologics Discovery and Design, Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois, USA.

Monoclonal antibodies in immunodiagnosis and immunotherapy
|July 22, 2024
PubMed
概括

开发稳定的哺乳动物细胞系对于生物制造至关重要. 跳跃转化酶系统提供了一种更快,半站点特定的整合方法,用于生成高产,稳定的中国子卵巢 (CHO) 细胞池,用于体外诊断 (IVD) 生产.

关键词:
抗体制造 制造 抗体制造细胞培养培养的细胞培养.在体外诊断 in vitro诊断再组合的复合方式.转换酶可以转换.

更多相关视频

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K
Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells
08:15

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

11.0K

相关实验视频

Last Updated: Jun 20, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.4K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K
Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells
08:15

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

11.0K

科学领域:

  • 生物技术是生物技术.
  • 细胞线发展发展 细胞线发展
  • 分子生物学分子生物学

背景情况:

  • 哺乳动物细胞系的稳定性对于生物制药和体外诊断 (IVD) 制造至关重要.
  • 细胞系发育的传统随机整合方法耗时,可能导致遗传不稳定.
  • 新技术旨在减轻与细胞系发育中的遗传不稳定性相关的风险.

研究的目的:

  • 评估跳跃转化酶介导的表达系统,以产生稳定的中国仓鼠卵巢 (CHO) K1 细胞池.
  • 评估CHO K1池的生产率和稳定性,用于生产用于IVD免疫测试的重组抗体试剂.
  • 将特定站点集成的效率与传统的随机集成方法进行比较.

主要方法:

  • 在CHO K1细胞中应用ATUM Leap-In转化酶系统进行半站点特定集成.
  • 生成稳定的CHO K1细胞池,用于生产四种重组抗体试剂.
  • 通过随着时间的推移产生一致的抗体来评估细胞系稳定性.
  • 评估L-Glutamine对细胞系稳定性和抗体标位的影响.

主要成果:

  • 在4个生成的CHO K1池中,有3个保持了稳定的生产率,适合制造,呈现出高抗体产量.
  • 一个CHO K1池显示,随着时间的推移,生产率下降,但衍生克隆显示可接受的稳定性.
  • 氨酸对细胞系/池稳定性表现出可变的影响,并显著影响了抗体产品标位.

结论:

  • ATUM Leap-In转化酶系统促进了用于IVD制造的高产,稳定的CHO细胞池的生成.
  • 使用Leap-In系统的半站点特定集成可以减少与传统随机集成方法相比的开发时间.
  • 开发的稳定池符合复合抗体生产的制造稳定性要求.